PWA
CRVS icon

Physician Wealth Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Physician Wealth Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.59K Hold
177
– – ﹤0.01% 1241
2025
Q4 		$1.36K Hold
177
– – ﹤0.01% 1462
2025
Q3 		$1.3K Buy
+177
New +$906 ﹤0.01% 1421

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Physician Wealth Advisors's CRVS Position: Q1 2026 in Review

Physician Wealth Advisors held its Corvus Pharmaceuticals (CRVS) position steady in Q1 2026 at 177 shares worth $2.59K. The position accounts for ﹤0.01% of the portfolio, ranked #1241.

Physician Wealth Advisors first reported a position in CRVS in Q3 2025 and has held it in 3 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Physician Wealth Advisors held 177 shares of Corvus Pharmaceuticals worth $2.59K as of Q1 2026.
  • Physician Wealth Advisors left its Corvus Pharmaceuticals share count unchanged in Q1 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Physician Wealth Advisors's portfolio in Q1 2026, its #1241 holding.
  • Physician Wealth Advisors first reported a position in Corvus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Physician Wealth Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.